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New procedure enables selective use of lymph node dissection

lntraoperative lymphatic mapping
elegant way to identify lymph node
metastases in melanoma patients
Like a number of tumors, cutaneou melanotumor, o are all of the other node , and formal
ma often spread through lymph channel to
lymph node di ection i not n ce ary.
regional lymph nodes. Becau of thi tendency,
"Thi procedure can help identify which paelective lymph node di section-removal oflymph
tient are mo t likely to benefit from lymph node
nodes before there is clinical e idence of meta ta - di ection and which patient probabl would
sis-has long been a tandard treatment for panot benefit," aid Merrick T. Ro , M.D., a ocitients with early stage cutaneou melanoma. While ate profe or in the Department of Surgical Onthis procedure has not been proven to prolong cology. "It allows us to be more selective about
survival, many surgeons believe that electi e lymph performing lymphadenectomy."
node dissection in a patient with micrometastases
can prolong the patient's life and in some cases Lymphoscintigraphy reveals nodes at risk
cure the disease.
Before performing intraoperative lymphatic
Until recently, howe er, thi approach in olved mapping, the surgeon must knm: which nodal
Merrick I. Ross is an
associate professor in the
a catch-22: electi e 1 mph node dissection could basin are at ri k for micrometa ta e . For melaDepartment of Surgical
benefit only those patients v ith micrometastase
noma on the arm or leg , the l) mphatic drainOncology
but determining
hether a patient had age patt ms are fairl pr dictable: the arm drain
micrometa ta es required a 1 mph node di secto the axilla, and the leg drain to the groin. For
tion. Thus, ome patients underwent unnece ary le ion on the trunk, hm e er the drainage patsurgery-a matter of concern becau e 1 mph node tern are ambiguou . A melanoma on the upp r
di ection i a major urgica1 procedure a ocitrunk might drain to the groin for e 'ampl or a
ated with a number of potential hort- and longmelanoma near the left axilla might drain to the
term complications.
right axilla. And sometime a le ion drain to
- - -- - - -- - - -- - -----+-l.-1.;utting~edg~proach-be.ing st11died_inn._.._·,.- .,_·_ -i-~...,..__.,-----4,..L.,,_.a_._._n..._,._,.Q......O~e__.__n._.._a,ud.. _._a.. __l_.._hu.,a. . ,_sJ.. _n.______.I__.__t_.;'sL.JoLI.Ja~t._1
_·
........1.L.Ln_.___.cau..mLL.LLm.L.l...'-'a..Lln_
cal trials at The Univer ity ofTexas M. D. Anderto find two nodal basin ," aid Ros , 'and it' not
son Cancer Center offers a way around this
unheard of to find three. We "' ill pursue the e
dilemma. Using this new technique-intraoperamultiple nodal basins if nece ary.'
ti e lymphatic mapping and sentinel node biWhen the drainage patterns are ambiguous,
opsy-surgeons can determine the disease status lymphoscintigraphy is used to identify the nodal
of an entire lymph node basin by identifying,
basins at risk. This simple outpatient procedure is
removing, and examining a single special lymph typically performed several days before the intranode called the sentinel node.
operative lymphatic mapping and sentinel node
The sentinel node is the first node that the
biopsy. Lymphoscintigraphy begins with injecdermal lymphatics around a tumor drain to. Studtion of a radiolabeled colloid into the skin adjaies have shown that the pathologic status of the cent to the tumor. Over the course of a few
sentinel node accurately predicts the status of all minutes, the colloid passes through the dermal
of the lymph nodes along that drainage pathway. lymphatics to one or more lymph node basins,
In other words, if the sentinel node is free of where it is taken up by the macrophages in the
lymph nodes. A
continued on page 2
Treatment Update
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scintillation camera is then used to document the
path of the radiolabeled colloid through the lymphatic system. This is the same path that tumor
cells would follow if they broke away from the
primary lesion and entered the lymphatics.
"Lymphoscintigraphy doesn't tell us if there's
tumor in these areas," said Ross, "but it does tell
us that if tumor had traveled to a lymph node area,
that's where tumor would most likely be." With
this information in hand, the surgeon can plan the
intraoperative lymphatic mapping.
Dye, radiolabeling help locate sentinel node
Intraoperative lymphatic mapping and sentinel node biopsy is performed at the same time as
wide local excision of the primary tumor. The
operation is typically performed as an outpatient
procedure, with patients staying in the clinic about
23 hours.
About an hour before surgery, the patient is
taken to the nuclear medicine station, where technicians inject a radiolabeled colloid into the skin
adjacent to the tumor. The next stop is the operating room, where the surgeon injects a blue vegetable dye called isosulfan blue near the tumor.
While the blue dye travels through the lymphatic system, the surgeon scans the skin over the
nodal basin with a hand-held, portable gamma
probe, looking for areas with high levels of radioactivity. These "hot" areas signal lymph nodes that
have taken up the radiolabeled colloid; the hottest
area corresponds to the sentinel node.
The surgeon makes a small incision directly
over the sentinel node and inserts the gamma
probe, which is covered with a sterile sheath. By
moving the probe around, the surgeon can further
pinpoint the area of high radioactivity. Within this
region, the surgeon hunts for a blue-stained nodethe sentinel node-and carefully dissects it.
How does the surgeon know that the bluestained node in question is actually the sentinel
node? "There's a time element involved," said
~osS:-''Tf you wait too long, the dye can pass
through several nodes. We generally do the biopsy
within 20 minutes after injecting the blue dye."
The lymphatic channels connecting the nodes are
also stained blue, so "once you find the node, you
can trace back the lymphatic channels leading to it
to make sure it's the first node-that there isn't a
node before that one."
When surgeons at M. D. Anderson Cancer
Center first performed intraoperative lymphatic
mapping, they relied on the blue dye alone to
localize the node. The gamma probe was intro-

duced about one and a half years ago. "When we
were using just the dye," said Ross, "we were
confident between 85 and 90 p ercent of the time
that the node we found was the sentinel node,
because we were limited to visual inspection. Since
we've been using the gamma probe, we almost
never have a concern about n ot finding the appropriate lymph node."
With use of the gamma probe, said Ross, "we
know where the sentinel node is going to be. This
allows us to make a very small incision and also
makes the operation much quicker."
After the sentinel node is removed, it is examined by a pathologist. If the node looks clinically
suspicious, it is examined by froz en section. The
results are available in a matter of minutes, and if
the node contains metastases, the surgeon can
proceed with a formal lymph node dissection in
the same operative setting. However, "if the node
looks normal," said Ross, "we prefer to evaluate
the lymph nodes by serial sectioning with permanent sections. It is more accurate, and we are less
likely to miss tumor. We are looking for a small
amount of microscopic disease, and you can sometimes lose important tissue when you do a frozen
section." In this case, if the sentinel node contains micrometastases, the lym ph node dissection
is performed at a later date. New procedure offers several advantages
This new procedure offers a number ofimpor- .
tant advantages over traditional treatment~ chief
among them the ability to avoid formal lymph
node dissection and its attendant risks-including
obvious scarring, nerve damage, or lymphedemain patients who would not benefit from the procedure.
The new procedure may also allow better detection of micrometastatic disease. "There are patients who are thought to be lymph node negative
who eventually have a recurrence," said Ross. "We
think that a number of these p atients are actually
lymph noae pos1t1ve, but we missed tfie
micrometastases because we weren't able to look
at every lymph node carefully enough." With a
traditional lymph node dissection, detailed examination of all the nodes removed is not feasiblethe time and expense involved are prohibitive.
However, with only one or two n odes to focus on,
said Ross, "it is more feasible to perform very
careful examination by using serial sectioning and
immunohistologic studies," and thus the chances
of detecting micrometastases are greater. The
sentinel nodes are also thought to be the nodes
continued on page 7
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Cooperative multicenter clinical trials a boon to lung cancer therapy

Combined chemotherapy and
radiation therapy bringing hope for
inoperable lung cancer
In the United States, lung cancer has been
surpassed by cancers of the prostate and breast in
sheer numbers of cases, but lung cancer has been
and remains the number one cancer killer. About
177,000 new cases oflung cancer are expected in
this country in 1996, and about 159,000 people
will die of lung cancer during the same period.
What these numbers suggest-that most people
who have lung cancer will die of it-is true. Only
about 13% of patients with lung cancer are alive
five years after the cancer is diagnosed.
The primary reason for lung cancer's low survival rate is that the disease is rarely diagnosed in
its early stages, when it is most successfully treated.
Lung cancer is usually not betrayed by symptoms
before it reaches an advanced stage. Thus, more
than 70% of lung tumors are diagnosed only
when they have grown very large or metastasized.
For these advanced tumors, surgical resection is
rarely possible. Now, multiple modality regimens
being developed at The University ofTexas M. D.
Anderson Cancer Center may offer patients with
locally advanced, inoperable lung cancer (stage
III) a longer and more comfortable life.
For the past several years, clinical research in
lung cancer has focused on earlier detection, but
little headway has been made. Much of the emphasis is now shifting to chemoprevention and to
molecular techniques for detecting premalignant
conditions and predicting cancer risk. Until clinical applications of those techniques become avail:J.ble, however, standard treatments-chemotherapy and radiation therapy-are the best hope
for patients with inoperable lung cancers. Ritsuko
Komaki, M.D., F.A.C.R., radiation oncologist
and professor in the Department of Radiotherapy
at M. D. Anderson, related how these treatments
for lung cancer have been refined continuously
over the past two decades.

Radiation dose escalation prolonged life
"Until the early 1970s," explained Komaki,
"the standard treatment for locally advanced, inoperable lung cancer was radiation therapy. This

therapy was largely palliative, helping to open the
airway and relieve pain, cough, and hemoptysis.
The two-year survival rate for patients who underwent this therapy was about 10%. Then, in
1973, therapy for these cancers began to change,
a process still underway today." The Radiation
Therapy Oncology Group (RTOG), a group of
investigators from many institutions who do collaborative research on radiation therapy for cancer, began treating patients with locally advanced
tumors with a higher dose of radiation than had
been used before, 60 Gy over six weeks . In 1980,
RTOG reported that the patients who received
the higher dose had a two-year survival rate of
20%, double that of the patients who received the
conventional dose (20 to 40 Gy). From that
time, 60 Gy over six weeks became the standard
radiation dose for inoperable lung cancer.
The patients in the RTOG trial had non-small
cell lung cancer, which accounts for about three
of every four lung cancers and includes squamous
cell carcinoma ( the most common type), adenocarcinoma, and large cell carcinoma. These cancers tend to grow and spread less rapidly than
small cell lung cancer, which grows quickly,
spreads aggressively, and is almost always in an
advanced stage when diagnosed.

Treatment Update

Ritsuko Komaki is a
professor in the Department of Radiotherapy

Combined chemoradiation: the rationale
Some patients with locally advanced, inoperable non-small cell lung cancer received only
chemotherapy. In these patients, the tumor usually recurred very quickly, typically in the chest or
brain. Although chemotherapy prevented or limited metastasis, it did not prolong life; moreover,
it disrupted bone marrow function and normal
tissues, putting a much greater strain on the
patient than local therapies. On these grounds,
chemotherapy has been rejected as the sole treatment for stage III lung cancer. But once certain
chemotherapy drugs became available that increase tumor sensitivity to radiation, the combination of chemotherapy and radiation began to
make sense. The rationale was that chemotherapy
could not
continued on page 4
page 3
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only prevent the cancer from spreading to other
parts of the body but also sensitize the tumor so it
could be killed more effectively by radiation.
This rationale was validated when another collaborative research group called the Cancer and
Leukemia Group B ( CALGB) conducted a large
randomized study of chemoradiation in patients
with stage III lung cancer. This trial compared two
regimens: one consisted of chemotherapy followed by standard daily radiation therapy (60
Gy) and the other of radiotherapy as the sole
treatment. The two-year and five-year survival
rates in the group that received the combination
regimen were 35% and 19%, significantly higher
than those in the group that received only radiation. "After that study," said Komaki, "combined
chemotherapy and radiation therapy became the
standard instead of radiation therapy by itself.
However, we didn't know the best timing or
sequence of these treatments, and we still don't,
although we have gotten a lot closer. All of our
clinical trials are now designed to refine and im prove these combinations."
Hyperfractionation allows higher doses
Radiation dose is also an issue. "We know that
a very high dose of radiation is best for controlling stage IIIB lung tumors," said Komaki, "but
most patients cannot withstand these doses. We
reasoned that patients with a good performance
status who have lost relatively little weight (less
than 5 % of body weight) might tolerate high
radiation doses with fewer side effects later if they
were given a smaller fraction twice daily rather
than a larger fraction once daily. This strategy,
called hyperfractionation, has been an effective
innovation in that it allows a somewhat higher
dose ( 69. 6 Gy) to be given over the same period
or a slightly shorter period."
The hyperfractionation concept was tested in a
large randomized trial in which another collaborative research organization, the Eastern Collaborative Oncology Group (ECOG), worked with RTOG.
This study compared three regimens: sequential
chemotherapy and standard daily radiation therapy
as in the CALGB study, hyperfractionated radiation
therapy (69 Gy), and once-daily radiation therapy
(60 Gy). The two-year survival rate in the combined
modality group was 35%, just as it had been in the
CALGB study. The rates for the twice-daily and
once-daily radiation therapy groups were 29% and
24%, respectively.
"These studies," noted Komaki, "showed us
that sequential chemotherapy and radiation would
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prolong life. European investigators found that
patients who received simultaneous radiosensitizing
cisplatin and radiation therapy also had better survival rates than patients who received only radiation. Opinion in lung cancer treatment began to
favor concurrent rather than sequential chemotherapy and radiation therapy. Here at M. D.
Anderson, we planned a series of trials that would
compare the two approaches."
The first was a phase I trial of concurrent chemotherapy and hyperfractionated radiation
therapy. Patients received twice-daily radiation
(69 .6 Gy) with cisplatin or etoposide. When the
patients in this trial had a higher two-year survival
rate than historical control patients who received
only radiation, Komaki and her colleagues planned
a phase II trial to determine the efficacy of con current chemotherapy and hyperfractionation.
Balancing therapeutic and side effects
In both the phase I and II trials , many patients
developed esophagitis, sometimes severe. Thelining of the esophagus is very sensitive to radiation,
and the damage it sustained was exacerbated by
the chemotherapy. The esophagitis made swallowing difficult, and about one third of the patients in
the trial were affected severely enough that they
lost 10% or more of their body weight.
"As uncomfortable as this esophagitis was,"
recalled Komaki, "it disappeared in most of the
patients within three weeks of completing the
therapy. Most began to regain the lost weight
within a month of completing therapy. And, the
two-year survival rate for the 7 6 patients in this
trial was almost 40%. Despite the side effects,
RTOG agreed to conduct a multicenter phase III
trial that included concurrent chemotherapy and
hyperfractionated radiation therapy as one of the
three arms. The purpose of this study is to look
for regimens that are as effective as standard
therapy and more tolerable to patients."
This phase III trial, which has recruited about
one third of its target 600 patients at 25 RTOG
institutions, is comparing three regimens: standard sequential chemotherapy (weekly for five
weeks) plus once-daily radiation therapy, concurrent chemotherapy (weekly for five weeks) plus
once-daily radiation therapy, and concurrent
weekly chemotherapy plus hyperfractionated radiation therapy. Patient enrollment in the trial
should be completed by 1997. Komaki said the
RTOG investigators have had no problem recruiting patients into the study, despite the side
effects of the combined modality regimens.
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One recently completed randomized phase II
trial compared sequential chemotherapy and oncedaily radiation therapy with concurrent chemotherapy and hyperfractionated radiation therapy.
The two-year survival rates were the same, about
35%. The concurrent therapy group received a
somewhat lower dose of etoposide than in the
earlier trial, which reduced the severity of
esophagitis.
Small cell tumors respond to combination
therapy
Combined chemotherapy and radiation therapy
have also helped patients with the less common
locally advanced and inoperable form of small cell
( or oat cell) lung cancer, which is referred to as
limited disease rather than locally advanced. These
cancers have always presented a particular treatment challenge . "Fifty years ago," said Komaki,
"small cell lung cancer was not curable at all, not
even limited disease . Almost everybody who had it
died. Investigators began using radiation therapy
on these patients, and maybe 5% of them survived.
Chemotherapy regimens were somewhat effective,
but again the side effects-neurotoxicity and bone
marrow suppression-were severe, and local recurrence was common. In the face of the same
challenges, the development of combination therapies for limited small cell lung cancers paralleled
that for locally advanced non-small cell lung cancers.
"Twenty years ago," Komaki went on, "about
10% of patients with limited small cell lung cancer
could be cured with combination chemotherapy
and radiation therapy. Through a series of trials
begun at the N ational Cancer Institute and continued by RTOG and ECOG, we have tested
doses, timing, and duration of treatments, looking
for the combination that will stop cancer and
prevent recurrences. Because ofits aggressiveness,
however, limited small cell lung cancer requires
higher doses and more intensive treatments than
non-small cell lung cancer. More and more, clinical trial results are supporting concurrent chemotherapy and hyperfractionated radiation therapy."
A trial that originated at M. D. Anderson and is
now in phase II at several RTOG centers is comparing two more intensive regimens of concurrent
chemotherapy and hyperfractionated radiation
therapy. The radiation is given in a shortened threeweek schedule; this might allow patients to take a
bone marrow-stimulating drug to support the more
aggressive chemotherapy needed to limit metastasis
of small cell lung cancer.

Concurrent therapies enhance local control
There is evidence that concurrent therapy reduces the rate of local cancer recurrence in both
small cell and non-small cell lung cancers. Explained Komaki, "If lung cancer comes back, or
spreads to other places, such as the brain or liver or
bone, it usually happens within 15 months after
treatment. This is the why the two-year survival
rate is a landmark in this disease. However, patients who have had one lung cancer are at risk of
having a second cancer, and second lung malignancies may not develop until three or even five or
more years after the treatment. Once patients have
survived two or three years after treatment for
their initial cancer, they are eligible for
chemoprevention studies to help prevent these
second cancers from developing. But the first thing
we have to do is help patients survive the first two
years."
How close are they to that goal? "We look very
closely at the results of these trials," said Komaki.
"We look for what works and what does not, and
from that we plan the next trial. From these trials,
we have learned that twice-daily radiation reduces
the risk oflocal recurrence, and that chemotherapy
helps prevent or stop metastasis and enhances the
effectiveness of local radiation. We need to put
them together to cure lung cancer, but for how
long? In what order? Then, we have the problem
of patient tolerance. Finding just the right combination of therapies is a delicate business. But we
are finding new ways . We are making progress."
Komaki and her colleagues at M. D. Anderson will
soon begin using three-dimensional radiation
therapy in lung cancer patients, which allows greater
precision and thus better protection of normal
tissues and sensitive structures such as the esophagus.
Komaki and her fellow RTOG investigators are
ambitious. "With our current trial," commented
Komaki, "we are aiming for a two-year survival
rate of 50%. But even if we improve the survival
rate by only 1 %, that means a lot of lives."
-KATHRYN

L.

HALE

REFERRALS. Physicians who have questions may
write Dr. Komaki, Department of Radiotherapy, Box
97, The University of Texas M. D. Anderson Cancer
Center, 1515 Holcombe Blvd., Houston, TX 77030,
or call (713) 792-3420. Those who would like to refer
a patient may call the New Patient Referral Office at
(800) 392-1611 or (713) 792-6161. ■
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Referrals
continued from page 8

"Since the policy change to self-referral," continued von Eschenbach, "the New Patient Referral Office is supporting the institution's transition
to a multidisciplinary, disease site approach to
cancer care." The office created four teams of
referral specialists, each of which concentrates on
certain types of cancer or cancer sites. Each team
is headed by a registered nurse with experience in
the care of patients with those types of cancer.
After extensive retraining, each team has an understanding of the medical criteria for accepting
patients to M. D. Anderson. The referral specialists have checklists of specific questions that need
to be answered when screening patients with
each type of cancer. The lists of questions were
developed by the cancer center's medical services.
Referral specialist first contact
"The person calling with the referral, whether
patient or physician, will first talk to a referral
specialist," said von Eschenbach. "Referring physicians who wish to speak to an M. D. Anderson
staff physician about a case will, of course, be
patched ·through to the physician on call for that
service, just as they always were. But because our
referral specialists are so knowledgeable, it may not
be necessary." The new referral process is designed
to offer maximum convenience to referring physicians. "Doing more screening up front is helping
save time for referring physicians; it facilitates the
process of getting two busy physicians together
on the telephone."
To simplify and hasten the referral process,
von Eschenbach recommends that physicians
making referrals to M. D. Anderson have all of
the relevant information about the patient handy
when they make the call. M. D. Anderson's Clinical Staff Directory includes instructions to help
referring physicians prepare for the questions they
will be asked. The referral specialists will ask
many questions about the patient's medical status and the treatment the patient has received. If
the patient clearly falls within the parameters set
out by the medical service, the referral specialist
will also ask for demographic and financial information about the patient. The answers to all of
these questions will determine whether the pa tient is admitted to the appropriate outpatient
clinic at M. D. Anderson.
If the referring physician is able to supply all of
the needed information, the referral specialist may

page 6

be able to immediately accept the referral pending
verification of the patient's insurance coverage.
If, however, the patient does not clearly fall within
the medical parameters, the case will be reviewed
by the nurse team leader and, if necessary, a staff
physician. If the referring physician does not have
demographic or financial information about the
patient, the referral specialist will contact the patient for that information. If all acceptance criteria
are satisfied and the financial information is verified, an appointment will be set for the patient.
Complex cases handled by staff physicians
von Eschenbach emphasized that the referral
specialists cannot refuse referrals. "If a patient
falls outside of the established medical criteria for
acceptance, all that means is that the patient 's
case is complex enough that the referral specialist
can't make the decision whether to give an ap pointment. That decision will be made by a staff
physician. The referral specialist is there to collect
information and, in some cases, accept the referral
without further medical review. The referral specialist will also relegate a referring physician's questions about specific treatment protocols or clinical
trials to the medical staff."
Patient self-referrals are assessed by exactly the
same medical and financial questions as physician
referrals. "However," explained von Eschenbach,
"self-referrals are more complicated because we
cannot, unfortunately, always take a patient's word
about his or her cancer. We accept referrals only
from patients who have already been diagnosed
with cancer, and we need copies of medical reports
documenting the cancer. The first questions we
always ask patients when they call the New Patient
Referral Office are when and how the cancer was
diagnosed. We ask them the name of their physician
and whether we can contact the physician; we also
ask them to send a copy of their pathology or
radiology report. The requirements vary by the
medical service. In most cases these reports can be
sent to us by fax to keep the process moving."
New procedures speed patient check-in
New Patient Referral Office services don't stop
when the referral is accepted. The referral specialist will call the patient to let him or her know
about the referral and to set up an appointment.
This can often be done as part of the call in which
the patient gives demographic and financial information. "This way," said von Eschenbach,
"when the patient comes in for his or her first
visit, much of the paperwork is done. Patients
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don't spend as much time in Registration as they
used to. The ch art is already made up. Usually
they just have to sign a few forms."
von Eschenbach is enthusiastic about the
changes in the N ew Patient Referral Office. "The
new procedures h ave decreased our turnaround
time, giving referring physicians a much quicker
response. Overall, I think, the process is working
much better than it did before the change in
referral policy."
-KATHRYN L. HALE

REFERRALS. Physicians who have questions or
would like to refer a patient may call the New Patient
Referral Office at (713) 792-6161 or (800) 3921611. The Clinical Staff Directory is available by calling the Office ofReferral Relations at (800) 252-0502.
It is also available on M. D. Anderson's home page on
the World Wide Web (http:/ /utmdacc.
uth.tmc.edu). ■

Callers to th e New Patient Referral Office telephone numbers will also be offered, besides the
physician referral and self-referral options, M. D. Anderson's Information Line (Option 3), which
was instituted after the change in referral policy to help patients navigate the self-referral process
and to help them prepare for their visit to M. D. Anderson. The Information Line is staffed by health
information specialists trained to respond appropriately to callers' questions about programs,
services, and treatment at the cancer center. The line is open to patients at M. D. Anderson,
patients at other institutions, and the general public.
To use the M. D. Anderson Information Line, call (71 3) 792-61 61 or (800) 392-1611 and choose
Option 3.
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Lymphatic mapping
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most likely to harbor micrometastatic disease, so
focusin g on those nodes is the best strategy for
detecting micrometastases.
Early detection of disease spread to lymph
nodes is especially important now that alphainterferon has been identified as an effective adjuvant therapy for patients with lymph node spread
of melanoma. The earlier micrometastases in regional lymph nodes are identified, the earlier
patients can receive this therapy.
Procedure also u seful for other types of cancer
Encouraged by the success of intraoperative
ly~phatic mapping and sentinel node biopsy for
the treatment of cutaneous lymphoma, surgeons
are investigating the role of this procedure in
treating breast and other types of cancer. "Right
now, the standard of care for patients who undergo surgery for breast cancer is to include an
axillary lymph node dissection, but now that we're
seeing breast cancer earlier, a lot of these patients
don't have lymph node involvement," said Ross.
In a preliminary trial of sentinel node biopsy in
breast cancer patients, M. D. Anderson surgeons
found only one false-negative result in a series of
35 patients. According to Ross, some areas of the

breast drain exclusively to the internal mammary
chain-not the axilla, the traditional site oflymph
node dissection in breast cancer patients. "For
patients with tumors in those areas of the breast,"
he said, "sampling the axilla may be misleading.
Using intraoperative lymphatic mapping with a
gamma probe, it is possible to access the internal
mammary nodes. That has been out of vogue for
some period of time, but now that we're understanding lymphatic drainage better, it may be
coming back into our staging evaluations of patients with breast cancer."
Intraoperative lymphatic mapping can also be
used for melanomas of the vulva and for other skin
cancers that spread to lymph nodes-some of the
adnexal tumors of the skin, Merkel cell tumors of
the skin, and some of the more aggressive squa mous cell cancers. ''Tfiis technique," saicrRoss,
"is applicable to essentially any solid tumor that
has a predilection for lymph node metastases."
-STEPHANIE P. DEMING
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REFERRALS. Readers who would like more information may write Dr. Ross, Department of Surgical
Oncology, Box 106, The University of Texas M. D.
Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, or call (713) 792-7217. To refer a
patient, call the New Patient Referral Office at (800)
392-1611 or (713) 792-6161. ■
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Streamlined procedures save referring physicians time

New Patient Refe"al Office changes
with M. D. Anderson's refe"al policy
Referral

Drew von Eschenbach is
operations manager, New
Patient Referral Office

When The University of Texas M. D. Anderson Cancer Center was officially established by
the 47th Texas Legislature in 1941, House Bill
No. 268, Chapter 548, specified that "Every
application shall be accompanied by a written
request from the attending physician of the pare e tin t e mis 1 of s ch atien . "
That policy remained in place for 54 years. On
March 28, 1995, Texas Governor George W.
Bush signed new legislation that, for the first time
in M. D. Anderson's history, allows patients to
refer themselves to the center for cancer care.
Although the new policy gives patients greater
flexibility and choice in seeking cancer care, M. D.
Anderson encourages all patients to seek referral
through their physicians. Physician referral not
only simplifies the referral and transfer process for
patients, said Drew von Eschenbach, operations
manager of the New Patient Referral Office, but

helps optimize patient care and outcomes through
the continued involvement of patients' hometown physicians. Patients have embraced the new
policy, however, and in one year patient selfreferrals have grown to about 25% of all new
patient referrals to M. D. Anderson.
New referral procedures in place
The New Patient Referral Office used the
policy change as an opportunit to change its
procedures. "When there was onl ph sician
referral to M. D. Anderson, the staff in our
office served primarily as operators, ' said on
Eschenbach. "We connected an outside physician who wanted to refer a patient to the center
with a staff physician from the appropriate service. If the physicians concurred that a referral
to M. D. Anderson was appropriate, , e would
take over, setting up the appointment.
continued on page 6

